"The initial focus of our platform technology is a Transcatheter Mitral Valve Implantation (TMVI) system designed to be an effective alternative to open-chest surgery for treating mitral regurgitation. The Company's mission is to develop and commercialize cost effective, catheter based valve replacement systems that restore long term function to patients with failing mitral valves."

                                                                                       J. Brent Ratz, Co-Founder, President and Chief Operating Officer